ReviewWorld journal of gastrointestinal oncology2021
Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature.
Review in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The Geography of Liver Resection: Travel Distance, Facility Volume, and Access to Specialized Care in an Urban Setting.Annals of surgical oncology · 2026Article
- The Evolving Role of Living Donor Liver Transplantation in the Management of Colorectal Liver Metastases.Current oncology (Toronto, Ont.) · 2026Review
- Molecularly informed preoperative and response-adapted management of colorectal cancer: evidence, decision boundaries, and emerging directions.Frontiers in oncology · 2026Review
- Artificial Intelligence (AI) and Liquid Biopsy Transforming Early Detection of Liver Metastases in Gastrointestinal Cancers.Current cancer drug targets · 2026Review
- Short- and Long-Term Outcomes After Hepatectomy in Patients Receiving Triplet Versus Doublet Preoperative Chemotherapy for Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Data-driven identification and semi-automated quantification of molecular targets for tumour-imaging of colorectal liver metastases and primary colorectal tumours.EJNMMI research · 2025Article
- Tissue-specific antitumor NK cell subsets identified in colorectal cancer liver metastases express candidate therapeutic targets.The Journal of clinical investigation · 2025Article
- Radiofrequency ablation with or without capecitabine maintenance therapy for lung oligometastases from colorectal cancer.World journal of gastroenterology · 2025Article
- Mitigation of Racial and Ethnic Disparities in Surgical Treatment and Outcomes of Metastatic Colorectal Cancer in a Closed Health Care Delivery System.The Permanente journal · 2025Article
- The Role of KRAS Status Among Patients Undergoing Staged Versus Simultaneous Resection for Synchronous Colorectal Liver Metastases.Journal of surgical oncology · 2025Article
- Combination of Irreversible Electroporation andCancers · 2025Review
- International Validation and Refinement of Oncological Borderline Resectability Criteria for Hepatocellular Carcinoma Using Tumor Burden Score to Predict Survival.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities.Frontiers in immunology · 2025Review
- Preoperative CT-based morphological heterogeneity for predicting survival in patients with colorectal cancer liver metastases after surgical resection: a retrospective study.BMC medical imaging · 2024Article
- Constructing a prognostic model for colorectal cancer with synchronous liver metastases after preoperative chemotherapy: a study based on SEER and an external validation cohort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Article
- A contemporary view on vascular resections and reconstruction during hepatectomies.Updates in surgery · 2024Review
- Neoadjuvant Statistical Algorithm to Predict Individual Risk of Relapse in Patients with Resected Liver Metastases from Colorectal Cancer.Biomedicines · 2024Article
- Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles.International journal of molecular sciences · 2024Review
- Nomograms for predicting overall survival in colorectal cancer patients with metastasis to the liver, lung, bone, and brain.Cancer causes & control : CCC · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal carcinoma (CRC) is one of the leading causes of cancer-related deaths worldwide, and up to 50% of patients with CRC develop colorectal liver metastases (CRLM). For these patients, surgical resection remains the only opportunity for cure and long-term survival. Over the past few decades, outcomes of patients with metastatic CRC have improved significantly due to advances in systemic therapy, as well as improvements in operative technique and perioperative care. Chemotherapy in the modern era of oxaliplatin- and irinotecan-containing regimens has been augmented by the introduction of targeted biologics and immunotherapeutic agents. The increasing efficacy of contemporary systemic therapies has led to an expansion in the proportion of patients eligible for curative-intent surgery. Consequently, the use of neoadjuvant strategies is becoming progressively more established. For patients with CRLM, the primary advantage of neoadjuvant chemotherapy (NCT) is the potential to down-stage metastatic disease in order to facilitate hepatic resection. On the other hand, the routine use of NCT for patients with resectable metastases remains controversial, especially given the potential risk of inducing chemotherapy-associated liver injury prior to hepatectomy. Current guidelines recommend upfront surgery in patients with initially resectable disease and low operative risk, reserving NCT for patients with borderline resectable or unresectable disease and high operative risk. Patients undergoing NCT require close monitoring for tumor response and conversion of CRLM to resectability. In light of the growing number of treatment options available to patients with metastatic CRC, it is generally agreed that these patients are best served at tertiary centers with an expert multidisciplinary team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.